
Zhitong Finance App News, Deshijia (01846) announced that on November 16, 2026 (after the trading period), Shanghai Deshijia Ophthalmology Co., Ltd., Guangzhou Deshijia Ophthalmology Clinic Co., Ltd. and Beijing Deshijia Ophthalmology Clinic Co., Ltd. will each acquire 30% of their shares in Shanghai Lingrui Enterprise Development Co., Ltd., at a total cost of RMB 33.23 million. While such acquisitions are being carried out, each of these target companies will implement capital cuts to cancel their respective target shares. Upon completion, the seller will no longer hold any shares in such target companies, which will become wholly-owned subsidiaries of the companies.
Each of these target companies is an ophthalmology clinic operating and providing vision correction services in China. Prior to such acquisitions, these target companies were all non-wholly-owned subsidiaries of the company. The main strategic considerations in these acquisitions are to consolidate the Group's shareholding structure and achieve full corporate and operational control over these clinics.
By eliminating minority shareholders' interests, these acquisitions will significantly simplify the Group's corporate structure, eliminate potential operating frictions, and enhance the overall management efficiency of its expanding clinic network in China. Furthermore, the directors believe that these acquisitions will optimize the Group's financial position and resource allocation. Once completed, these target companies will become wholly-owned subsidiaries of the company, enabling the Group to control all of its financial performance and future profit growth. It is expected that this move will maximize the long-term return on shareholders' equity. Full ownership will also facilitate a seamless decision-making process and enable the Group to allocate capital, medical expertise and marketing resources more flexibly. Ultimately, this comprehensive integration will strengthen the Group's brand assets and reinforce the Group's competitive position in the field of high-end ophthalmic care and vision correction in China.